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ABSTRACT 
 
BACKGROUND: Diabetes is associated with an increased risk of micro- and macrovascular disease and 
mortality. Two main methods for diagnosis and control of type 2 diabetes are the measurements of blood 
glucose and glycosylated hemoglobin (HbA1c). These methods have some limitations where other 
techniques may complement. Hence, there is a need for other methods to be scientifically investigated and 
documented. Fructosamine is a biochemical marker of the amount of glycated proteins in the extracellular 
compartment of the blood and can serve as a complement to established blood markers of glycemic 
exposure. This thesis aims to evaluate fructosamine in relation to serum glucose and HbA1c and as a risk 
factor for type 2 diabetes (T2D), coronary heart disease (CHD) and death. 
METHODS AND RESULTS: For all studies in this thesis, subpopulations of the AMORIS cohort 
(n=812,073) were used. Study I. In 871 subjects with a documented diagnosis of type 2 diabetes (T2D), the 
mean fasting fructosamine was 2.7 mmol/L and the mean value for fasting glucose and HbA1c 
respectively was 9.6 mmol/L and 7.2%. The linear correlation of fructosamine and HbA1c was high 
(r=0.75). Across three repeated measurements within one year, fructosamine and HbA1c followed the 
changes of fasting glucose over time. At a fructosamine level of 2.5 mmol/L, the sensitivity for the 
diagnostic criteria for diabetes was 61% and the specificity 97%. Study II. In 338,443 subjects, we 
observed an increased incidence of myocardial infarction or death from coronary heart disease (CHD) in 
subjects with higher levels of fructosamine. A fructosamine level of ≥ 2.7 mmol/L was associated with an 
increased hazard compared to a reference group of normoglycemic individuals (Adjusted HR=2.1 (2.0-
2.2). Comparable risk increases of CHD events and all-cause mortality were seen in groups of 
hyperglycemia defined by HbA1c. Study III. We investigated the risk of all-cause mortality based on 
fasting fructosamine levels over a study period of 27 years and included 215,011 subjects without diabetes 
at baseline. We observed a U-shaped mortality in relation to levels of fructosamine. The lowest decile of 
fructosamine was associated with an increased mortality (HR=1.20; 95% CI: 1.16-1.24) vs. a reference 
group (decile 2 to 9). The HR was decreased when we adjusted for haptoglobin. Analyses of cause-
specific mortality showed increased risk ranging over several causes of death including an adjusted 42% 
increased mortality in lung cancer/COPD at low fructosamine levels. Study IV. We followed 296,436 
subjects for diagnoses of T2D over a total study period of 27 years. We described trajectories of several 
metabolic risk factors. More than 20 years before a diagnosis of T2D, BMI and fasting glucose as well as 
triglycerides were increased compared to a matched control population. The average 20-year risk of T2D 
was 8.1% in this population. This risk was considerably increased with higher values of these factors. 
CONCLUSIONS: The results from this thesis suggest that fructosamine levels are strongly associated 
with serum glucose and HbA1c and may be used as a complementary marker of glucose metabolism. High 
levels of fructosamine are associated with an increased incidence of myocardial infarction and death after 
adjustment for major cardiovascular risk factors. Several metabolic factors including BMI, fasting glucose, 
triglycerides and inflammatory blood markers, were increased in cases compared to matched controls 
more than two decades before a diagnosis of T2D. This suggests an early progression of the 
pathophysiology of T2D. 
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INTRODUCTION 
 
From the time when Aretaeus of Cappadocia in the 1st century introduced and originally described 
diabetes in medical literature,1 its methods of detection have been refined from only observable 
phenotypes via tasting of sweet urine to today’s blood tests of the current circulating glucose as 
well as long-term measurements of glycated proteins.2 
Still, only a few blood tests, which refer to the glycemic pathways, are commonly available to 
clinicians and epidemiological researchers, mainly glucose measurements and glycated hemoglobin 
(HbA1c). Limitations of these methods might make them unreliable in many individuals and in 
several situations.3 Therefore, it could be of value to find complementary blood markers and 
methods for the purpose of risk prediction as well as for the control of diabetes including risk 
prognosis of coronary heart disease (CHD) and death.4 
Fructosamine is a biochemical blood marker that is reflective of intermediate-term glycemic 
exposure over about three weeks. It has been suggested that fructosamine may be a useful marker 
in the clinical diagnosis and control of diabetes.5,6 In addition, fructosamine might functioning well 
as a risk marker in epidemiological research. Yet, reports describing the role of fructosamine in risk 
prediction of severe cardiovascular events and mortality as well as its role in the long-term risk of 
type 2 diabetes are rare. 
This thesis used data from the large AMORIS cohort with linkages to national health and mortality 
registers, and with an ample quantity of biochemical blood measurements including analyses of 
fructosamine. All measurements were performed in a standardized and well-documented way in 
nearly 500,000 individuals predominantly from the general working population in Stockholm, 
Sweden during 1985-1996. Hence, this cohort established a unique possibility to characterize 
fructosamine and its relations to established glycemic blood markers, diabetes, cardiovascular 
disease and mortality.  
The overall aim of this thesis is to increase current knowledge about fructosamine in relation to glucose and 
HbA1c, as a risk indicator for type 2 diabetes (T2D), coronary heart disease (CHD) and death respectively. 
The thesis also illustrates how long term metabolic status may alter from normal glycemic conditions into 
diagnosed type 2 diabetes.
Håkan Malmström   
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BACKGROUND
 
EPIDEMIOLOGICAL STUDIES 
In epidemiological studies, the researcher 
investigates the distribution of diseases in 
human populations often with the objective to 
find causal factors. Epidemiological studies 
can be either experimental or observational. 
With a biochemical exposure, which is the 
focus of the present thesis, the experimental 
design with random assignment to certain 
levels is inherently impossible. Still, the main 
objective of an experimental design, e.g. a 
randomized clinical trial (RCT), and an 
observational design respectively, is 
comparable, i.e. to evaluate an effect of a 
given exposure of risk factors or a treatment 
for a specified disease outcome. In contrast to 
RCTs, in which risk factors assume a random 
distribution in the treatment group and the 
non-treatment group respectively, an 
observational design suffers from issues that 
origin in the non-random allocation to groups. 
The essential principles of an RCT, which 
are; to enable effect comparison (i.e. usage of 
placebo), to enable population comparison 
(i.e. randomization procedure) and to enable 
information comparison (i.e. blinding 
procedures), are however strived for and 
pursued by the epidemiologist in the 
definition process of relevant observed 
exposure contrasts.7 Through adherence to 
and recognition of those principles in the 
designing of the observational study, the 
validity of the observed associations 
increases.  
DIABETES MELLITUS AND 
CARDIOVASCULAR DISEASE 
Diabetes mellitus (DM) is a chronic disease, 
characterized and diagnosed by 
hyperglycemia. The disease frequently gives 
rise to various complications, some of them 
serious. Globally, the prevalence of DM is 
high, about 415 million individuals, and it is 
projected by the International Diabetes 
Federation (IDF) that 642 million people will 
have the disease in 2040.8  
Cardiovascular diseases (CVD) refer to the 
circulatory system including the blood vessels 
and the heart.  Coronary heart disease (CHD) 
is a major condition included in the general 
concept of CVD.9 The risk of CHD 
commonly increases in hyperglycemic and 
dyslipidemic conditions,10 which induce 
atherosclerotic disease progression. 
Hyperglycemia per se, may not cause 
atherosclerosis but is associated with several 
mechanisms, which are atherogenic.11 Acute 
myocardial infarction is the ultimate stage of 
ischemic (i.e. oxygen restricted) conditions in 
the coronary arteries and in the myocardial 
tissue. Importantly, CHD is the leading cause 
of death globally.12 
Cardiovascular diseases are responsible for a 
major proportion of the total mortality 
worldwide.12 People with DM more often 
develop cardiovascular events compared to 
individuals with normal glucose tolerance.13  
In addition, DM and cardiovascular disease 
Håkan Malmström 
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accounts for a large proportion of the health 
related burden of societies.14 Interventions to 
reduce incidence include life style changes 
such as increased physical activity, healthier 
dietary habits, smoking cessation and 
pharmacological treatment of various 
conventional risk factors like hyperglycemia, 
blood pressure and dyslipidemia. 
Environmental exposures as those above, in 
combination with genetic factors15 may affect 
levels of biochemical blood particles, and 
consequently the risk of disease and 
complications. 
Types of diabetes 
The majority of individuals with diabetes can 
be categorized into two types with different 
etiology.16 One is with autoimmune etiology 
(type 1 diabetes (T1D)) and the other non-
insulin dependent and non-autoimmune (type 
2 diabetes (T2D)). In more recent decades, it 
has been realized that diabetes classification 
into autoimmune T1D and non-autoimmune 
T2D cannot be based (as previously) 
primarily on phenotypes,17 such as insulin-
dependent and non-insulin dependent 
diabetes but rather on the presence or absence 
of immunological markers for autoimmune 
disease. By biochemical criteria, non-insulin 
dependent individuals with diabetes who 
possess diabetes-specific antibodies (such 
individuals are commonly termed as LADA) 
would be classified as type 1 diabetes. In 
addition, the monogenic forms of MODY 
(Maturity Onset DM in Young) now single 
out from T2D. Genetic factors play an 
important role for T2D and for T1D.17 For all 
forms of diabetes, the risk of disease 
development is a combination of 
environmental and genetic factors.18 
Proportionally, T2D roughly accounts for 
90% of all individuals with diabetes. 
BIOCHEMICAL RISK MARKERS FOR 
DIABETES, CVD AND MORTALITY 
There are a number of glycemic, lipid related 
and inflammatory markers, which are 
important in casual pathways and/or in risk 
prediction of T2D and CVD. Brief 
descriptions of such markers included in this 
thesis are given below. 
Glycemic exposure 
Glucose 
High levels of circulating blood glucose is 
inherently a factor of importance for diabetes 
because of its essential and defining role in 
the diagnosis criteria.13,19-22 Increased glucose 
levels act as an indicator either for non-
functioning insulin production in the 
pancreatic beta cells and/or for reduced 
uptake of glucose in the body. Different 
interpretations of the glucose test are crucial, 
is it made in a fasting or a non-fasting state. 
In the fasting state, i.e. overnight fasted for at 
least eight hours, the glucose test reflects the 
hepatic production of glucose. Postprandial or 
after an externally glucose load, the test 
reflects the body uptake or the increase of 
glucose following a glucose load. Hence, the 
fasting glucose and glucose measured post-
prandial urge physiologically different 
interpretations.23 Fasting plasma glucose as a 
diagnostic marker has some limitations; 
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fasting status must be assured, long-term 
control of glucose needs to be performed by 
frequent measurements and intra- as well as 
intervariability could be substantial.24  
HbA1c 
HbA1c, formed via intracellular irreversible 
glycosylation of the hemoglobin, which is 
abundant in the red blood cells, has its usage 
as a long-term indicator of glucose 
exposure.2,24 It reflects the glycosylation over 
the whole lifetime of the red blood cell (120 
days and 60 days for hemoglobin) with the 
most recent month emphasized.25 Diseases 
affecting the red blood cells, e.g. hemolytic 
anemia, sickle cell anemia and impaired red 
blood cell turnover, can severely influence 
the accuracy of the HbA1c measurement.25 
The test is somewhat more technically 
difficult to analyze compared to standard 
plasma tests and therefore more expensive to 
perform than an ordinary plasma glucose test. 
Historically, one consideration for suggesting 
an important role of HbA1c in diagnostics 
and risk prediction of diabetes and its 
complications was its strong association with 
microvascular diseases, including 
retinopathy.26-28 
Non-traditional biomarkers of glycemic 
exposure 
Among non-traditional markers of glycemic 
exposure, fructosamine (more on page 23 ff.), 
glycated albumin and 1.5-Anhydroglucitol 
are debated.29 In contrast to fructosamine, 
glycated albumin is a test targeted to measure 
only the proportion of serum albumin being 
glycated. The 1.5-Anhydroglucitol measures 
the filtration of monosaccharides through the 
kidney and mirrors average glycemia in the 
preceding 2 to 14 days.30 With regard to the 
test of 1.5-Anhydroglucitol, it is uncommon 
in clinical practice and is expensive compared 
to measurements of fructosamine or glycated 
albumin.29 
Lipids and lipoproteins 
Serum/Plasma Cholesterol 
High levels of total cholesterol increases the 
risk of coronary heart disease (CHD) and 
death.31 The cholesterol may express 
atherogenic as well as protective effects on 
the vasculature depending on the type of 
lipoprotein responsible for transport.  
Cholesterol transported in low-density 
lipoprotein (LDL-C) penetrates the arterial 
wall and may exhibit atherogenic effects. In 
contrast, when transported in high-density 
lipoproteins (HDL-C), the cholesterol serves 
anti-atherogenically, hence, HDL-C works 
protectively on the risk of cardiovascular 
outcomes.13 
Serum/Plasma Triglycerides 
The direct effect of triglycerides in the 
promotion of CVD has been argued for 
decades. Yet, descriptive associations of 
triglycerides and CVD have been shown in 
several studies.32 Through its close inverse 
association to HDL-C, higher triglycerides 
are frequently observed in individuals with 
CVD and T2D. Reasons for the controversy 
about direct effects of triglycerides on CVD 
may be rooted in methodological issues and 
Håkan Malmström 
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in modest effects from those studies that yet 
suggested an association.32 It has been shown 
that independent effects of triglycerides are 
marginalized when also controlling for HDL-
C, however the effect of HDL-C remains.33 
The combination of high triglycerides and 
lower HDL-C is characteristic for atherogenic 
dyslipidemia 34 and for T2D. In addition, 
several other risk factors for both T2D and 
CHD are associated with high triglycerides 
35,36 and thus it is important to assess the 
overall atherogenicity of plasma in 
hypertriglyceridemia.32 Today, strong 
evidence suggests a casual role for 
triglycerides in CV disease.37-39 
Apolipoproteins 
Cholesterol and triglycerides are transported 
in blood embedded in lipoproteins, which are 
mainly classified as very low density 
(VLDL), intermediate density (IDL) low 
density (LDL) and high-density (HDL) 
lipoproteins respectively. Attached to each 
VLDL, IDL and LDL particle is one 
apolipoprotein B-100 (apoB). Thus, the sum 
of apoB particles, especially those attached to 
small dense LDL-particles, reflects the 
transport of potentially atherogenic 
cholesterol and triglycerides. Therefore, apoB 
has an atherogenic effect and has been 
demonstrated to be a strong risk factor for 
CVD outcomes 40,41 and to have similar effect 
as to that from LDL-associated 
cholesterol.42,43 Further, in younger ages, 
apoB has been reported to strike harder.43 On 
the other hand, apolipoprotein A-I (apoA) 
attaches to the anti-atherogenic HDL particle 
and higher levels of apoA are more 
protective. There are suggestions that the ratio 
of apoB and apoA would serve as the best 
predictor of severe CHD because of its 
balancing of atherogenic and anti-atherogenic 
characteristics.44-46 
Inflammatory related exposure 
Albumin 
Albumin is richly present in serum and has 
antioxidant properties. It is a negative acute-
phase protein47 and low serum albumin levels 
are reported to increase the risk of CVD.48-50 
In addition, changes in serum albumin levels 
has been shown to have protective effects in 
the development of the metabolic syndrome 
(MetS).47 
Haptoglobin  
Haptoglobin is an acute phase glycoprotein 
and is activated in protection to oxidative 
stress.51 Mainly it is synthesized from hepatic 
cells, but also exists in fat tissue. Elevated 
haptoglobin levels in serum are seen under 
acute inflammatory conditions, however 
chronic illness may also increase the 
haptoglobin levels and it has been linked to 
both diabetes and obesity51,52 as well as the 
MetS.53 Higher levels of haptoglobin have 
been associated with higher CVD risk.54-56 
Uric acid 
Uric acid (or urate), accumulates while purine 
compounds are broken down. It is an end-
product of this metabolism.57 Most often, the 
capacity of the kidney glomerulus is the 
limiting factor in the appearance of high uric 
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acid levels. Uric acid has been associated 
with development of T2D and possesses 
inhibitory effects on the insulin sensitivity.58 
Its casual effect on CVD is disputed57 
because of its close association to other CVD 
risk factors.59  
RISK FACTORS AND DIAGNOSIS OF 
TYPE 2 DIABETES 
Risk factors for T2D and CVD 
The risk of T2D increases with higher age 
and overweight/obesity as well as 
dyslipidemia, factors which may be 
associated with increased fasting blood 
glucose.13,60 These factors commonly appear 
clustered and are components of the 
metabolic syndrome (MetS),61 which also 
includes hypertension.13,62 The risk of T2D 
increases five-fold with the presence of MetS 
and cardiovascular events are markedly more 
common with the syndrome.62 Thus, most 
people diagnosed with T2D have one or more 
of the factors included in the MetS. The 
prevalence of MetS worldwide is increasing 
in parallel with a more sedentary life style, 
increasing overweight and abdominal 
obesity.62 With regard to T2D, other risk 
aspects to consider include family history of 
DM, ethnicity, tobacco usage and polycystic 
ovary syndrome in women.63 Dyslipidemia in 
subjects with T2D typically include 
hypertriglyceridemia, low HDL-C and normal 
LDL-C concentration.64 Although low LDL-
C may be found in subjects with T2D, those 
subjects many times have a higher amount of 
small dense LDL particles.64,65 Such particles 
more easily penetrate the arterial wall, 
eventually leading to atherosclerotic plaque 
building. In relation to small dense LDL, 
those subjects often have high apoB 
(atherogenic) levels and low apoA-1 
(atheroprotective) levels, leading to high 
apoB/apoA-1 ratio, a very strong risk factor 
for MI and stroke.40,44,45 
Risk prediction models for T2D 
Several risk prediction models have been 
developed for the identification of individuals 
at increased risk of T2D.66 These models are 
based on non-modifiable risk factors, such as 
age, sex, ethnic origin and family history of 
DM, but also on modifiable factors, including 
smoking, body mass index (BMI), dietary and 
alcohol habits, exercise, and lipid 
metabolism. Today, several models, using 
simple commonly available clinical 
characteristics, are used and show good 
prediction ability. The additional benefit of 
adding alternative novel blood markers to 
available risk prediction models is unclear.66 
In a recent review article, only one non-
glycemic biomarker, uric acid, was 
considered to have high predictive value (in 
addition to age, sex, BMI, smoking, family 
history and hypertension) for future T2D, 
whereas many biomarkers were shown to 
have low or moderate association with risk of 
T2D.67 Nevertheless, by using Mendelian 
randomization technique, uric acid was 
considered non-causally associated with 
T2D.68 Similarly, triglycerides levels did not 
show evidence of a casual relation to T2D.69 
Håkan Malmström 
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Diagnostic criteria of diabetes 
The diagnosis and control of DM are based 
on blood biomarkers. Diagnostic criteria 
defined in guidelines from American 
Diabetes Association (ADA), European 
Association for the Study of Diabetes 
(EASD) and the World Health Organization 
(WHO) form basis for combinations of 
fasting glucose, HbA1c and 2-hour glucose 
measured after an oral glucose tolerance test 
(OGTT).13,19-22 
In common, for all these diagnostic criteria is 
a fasting plasma glucose of ≥7.0 mmol/L 
(measured once or twice according to 
different guidelines) for the diagnosis of DM. 
OGTT with a 2hPG of ≥11.1 mmol/L is 
another way to establish a diagnosis of 
diabetes but are mainly for feasibility reasons 
less often used.13 A third parameter with 
which to diagnose diabetes has been added by 
ADA and WHO, i.e. an HbA1c of 6.5% (48 
mmol/mol). It should be noted that diagnostic 
criteria have been, and are still under debate 
and that diagnostic limits for fasting glucose 
have been lowered in recent years.70-72 
Furthermore, levels of fasting glucose in 
subjects without diabetes have shown a 
positive association with increased risk of 
CVD and mortality.73,74 
Early identification of type 2 diabetes 
For prevention purposes, it is of importance 
to early identify people of increased risk of 
developing T2D. The disease may gradually 
develop over several years preceding the 
diagnosis as reported in studies describing 
pre-diagnostic trajectories of metabolic risk 
factors.75-77 Differences in fasting glucose 
between cases and controls have been 
observed up to 13 years before the 
diagnosis.77 This progression over time has 
predominantly been shown for fasting and 2-
h plasma glucose, HbA1c and triglycerides.66 
Early identification of prediabetes is 
desirable, since the development into overt 
disease is largely preventable or possible to 
delay.78,79  
Screening for T2D has been demonstrated to 
gain cost efficiency and number of quality 
adjusted life years (QALYs).80,81 Although 
one large European randomized clinical trial 
initially reported no benefit of screening 
followed by intensive treatment versus no 
screening on all-cause-, cardiovascular-, 
cancer- or- other causes of mortality, over 10 
years,82 the authors later concluded that 
screening for T2D could be feasible but it is a 
challenging endeavor.83 Furthermore, follow-
up studies have shown, by simulation 
techniques, a reduced rate of cardiovascular 
events and all-cause mortality following 
screening with intensive treatment of detected 
cases.84 
Risk scores for predicting T2D may be useful 
in clinical practice. The number of scores 
published has increased dramatically from the 
year of 2000, and many are mainly based on 
social and behavioral characteristics rather 
than on biomarkers.85 Furthermore, only a 
small proportion, whereof the Finnish 
Diabetes Risk Score (FINRISC) is widely 
recognized,86 of all developed risk scores for 
T2D are used in clinical practice, likely due to 
poor validation and calibration.85 
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FRUCTOSAMINE 
Historical background 
Fructosamine, a ketoamine, was first 
synthesized in 1886 and was given the 
chemical reference “1-amino-1-deoxy-
fructose”.87,88 Although it was synthesized, 
the definition of fructosamine as a general 
term for glycated serum proteins, was not 
until 1982 introduced into the chemical 
literature.89 A few methods for measuring 
fructosamine were available, including 
affinity chromatography, thiobarbituric acid 
colorimetric procedure (TBA) and Nitroblue 
Tetrazolium Colorimetric procedure (NBT). 
Early, all of these methods demonstrated 
good discrimination of people with insulin 
dependent diabetes from individuals with 
normal glucose levels.87,90 
Biochemical aspect 
Fructosamines are particles formed in non-
enzymatic processes, primarily because of 
glucose bindings to circulating serum 
proteins.29,87 Fructose is proportionally low in 
the circulation because it is removed by 
hepatic processes,91 and therefore only a 
minor part of fructosamine origins from 
fructose bindings. Yet, a more rapid reaction 
with protein has been reported for fructose 
compared to glucose.92 Albumin constitutes a 
large proportion (up to 80%) of circulating 
proteins. Hence, a measurement of only 
glycated albumin does not account for all 
proteins being glycated. Immunoglobulins, 
lipoproteins and apolipoproteins as well 
undergo glycation and therefore are 
proportional quantities of fructosamine 
particles.93,94 The half-life (T½) of the most 
ample protein in blood, albumin, is shorter 
than the corresponding T½ for hemoglobin, 
thus, fructosamine reflects a shorter period of 
glycemic exposure compared to HbA1c. 
Fructosamine can be considered to be an 
intermediate-term measurement of glycemic 
exposure across the preceding 1-3 weeks87 
compared to HbA1c, which has a 
considerably longer accumulation rate of 8-12 
weeks. 
Clinical aspect 
Glycation of proteins that occurs in the 
extracellular matrix, i.e. the forming of 
fructosamine (extracellular glycation of 
proteins), may reflect different 
pathophysiological processes compared to 
intracellular glycation measured by HbA1c. 
Fructosamine converges to mean blood 
glucose over a shorter time compared to 
HbA1c. In certain situations, the shorter 
period a fructosamine test reflects may be an 
important complementary biomarker. This 
could be valid in gestational diabetes 
(GDM),94,95 in the evaluation of treatment 
intensification/de-escalation and in situations 
where earlier risk indications of various 
deleterious conditions warrant attention. In 
addition, evaluation of treatment response in 
clinical pharmacological studies may value a 
more rapid assessment of change. Some 
clinical limitations of the fructosamine test 
have been reported (e.g. in conditions of 
hypo- and hyperthyroidism, in myeloma and 
in nephrotic syndrome),96-99 which might 
limit its use. During pregnancy, dilutional 
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anemia may develop that might affect 
fructosamine negatively to lower levels not 
accurately reflecting current glycemia. 
Therefore, authors have reported that 
fructosamine may be unfavorably to use in 
investigation of GDM. Glycated albumin, 
which is not affected by diluted serum would 
be better recommended as a preferred test.94 
Despite a few limitations, fructosamine is a 
simple test measured in serum, fasting is not 
needed, it is inexpensive, and it is insensitive 
to any disorders of the red blood cells.29 
Altogether, fructosamine could be useful as a 
complementary biomarker in the clinical 
setting but more research guiding its 
applicability in different situations is 
warranted. 
Research observations in previous 
studies on fructosamine 
Descriptive associations 
Early research showed strong correlations 
between fructosamine, HbA1c and 
glucose.100-104 Some reported that non-linear 
correlations would be more appropriate to 
describe the associations.103 Most of these 
studies were of limited size and performed in 
subsets of subjects with different stages of 
diabetes and other medical conditions. More 
recently, the ARIC study reported 
correlations of the same magnitude as 
previously seen, between fructosamine and 
HbA1c.105 
Efforts to show associations of fructosamine 
with other factors (e.g. age, ethnicity, and sex, 
family history of T2D, BMI, hypertension, 
cholesterol and smoking) described an 
inverse association with BMI in patients with 
diabetes.25,106-110 In normoglycemic subjects, 
high values of fructosamine were more 
associated with being a man and with higher 
age.106 Furthermore, high fructosamine levels 
in subjects without diabetes were more 
common in individuals of African-American 
origin.29 
Cardiovascular outcomes 
Fructosamine has not until recently been 
linked to risk of CVD. In 2015, Selvin and 
colleagues found an increased risk of CVD in 
individuals with elevated fructosamine.105 
The study, based on subjects from the ARIC 
cohort, included both subjects with and 
without diabetes. Among subjects with no 
diagnosed DM, the study showed a 33% 
increased adjusted hazard for CHD, in the top 
percentiles of fructosamine (≥ 2.64 mmol/L), 
compared to a reference group. Restricting to 
subjects with diagnosed DM, a fructosamine 
of ≥2.70 mmol/L, which roughly 
corresponded to an HbA1c of 7%, was 
associated with an increased hazard of CVD 
outcomes and death compared to the same 
previous used reference group. Furthermore, 
diabetes patients below 2.70 mmol/L also 
showed a significant increased hazard 
compared to the reference group and the 
hazard ratio was of greater magnitude than 
that reported for subjects without diabetes 
who had higher fructosamine. In this study, 
by using identical percentile thresholds, 
fructosamine showed higher hazard ratios for 
CVD as compared to HbA1c.105 
The study by Selvin et al. showed an 
association between fructosamine and CVD 
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in a population based study and discussed 
fructosamine levels of 2.60-2.70 mmol/L as 
relevant thresholds for increased risk.105 In 
contrast to this study, the authors of a Finnish 
study with only diabetes-free individuals 
found no significant difference in CVD risk 
between the highest and lowest quartile of 
fructosamine.111 
Mortality 
In the ARIC study, high fructosamine levels 
were associated with increased all-cause 
mortality.105 This association remained after 
multivariate adjustment for traditional CVD 
risk factors and was particularly strong in 
T2D patients. The Finnish study observed no 
association between fructosamine and all-
cause mortality.111 
It has been reported that low fasting glucose 
levels may be associated with an increased 
mortality among individuals without DM.112 
In addition, this association was shown for 
low HbA1c levels and all-cause or CVD 
mortality.113,114 Whether low levels of 
fructosamine relate to a higher mortality has 
not been studied in detail but recent research 
suggests an elevated risk in the lowest range 
of fructosamine.105 
Progression of T2D 
Glycation of proteins occurs continuously in 
the circulatory system. The concentration of 
fructosamine typically increases with elevated 
plasma glucose concentrations and generally 
remains high in manifest DM.87 A limited 
number of studies have investigated the 
association between glycated serum proteins 
and DM103,115-117 and reported racial 
physiological differences in sensitivity of 
glycation.118-121 
One recent paper from the ARIC study found 
a five-fold increased risk of DM for 
individuals in the top percentiles of 
fructosamine, (≥2.64 mmol/L).115 This cohort 
study observed almost one thousand new 
cases of DM during the follow-up. A cohort 
study with fewer new cases of DM during a 
short follow-up, observed a four-fold 
increased risk for people in the top quartile of 
fructosamine (≥2.41 mmol/L), compared to 
people in the lowest quartile. The risk was 
much weaker after adjustment for HbA1c or 
glucose.117  
In addition to these two cohort studies, cross-
sectional studies have described higher 
fructosamine levels in people with known 
DM compared to people with no DM.103,116,118 
One study did not show any excess risk of 
higher fructosamine and furthermore reported 
an U-shaped risk curve.122 The authors 
suggested that genetic variation in 
glycosylation pathways was a possible 
explanation for this null association.122,123 
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CURRENT KNOWLEDGE GAP 
Fructosamine has not previously been 
extensively investigated with regard to T2D, 
micro-and-macrovascular complications and 
mortality. Strong correlations to the well-
known biochemical measurements of 
diabetes, i.e. fasting glucose and HbA1c, have 
been demonstrated. However, these were 
studies of limited size and in selected 
populations. Reports are inconclusive  
 
regarding the association of fructosamine and 
the incidence of CVD and mortality. Rarely 
the complete range of fructosamine is 
described and careful evaluation of risks at 
high as well as low levels is needed. The 
usefulness of fructosamine as a long-term 
predictor of T2D needs further investigation 
in a large population with long follow-up.  
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AIMS OF THE THESIS 
 
OVERALL AIM 
The overall aim of this thesis is to investigate fructosamine in relation to other major biomarkers of 
glucose metabolism, type 2 diabetes, cardiovascular disease and mortality. 
Specific aims 
a) To evaluate cross-sectional and longitudinal relationship between fructosamine and the 
established indicators of hyperglycemia; serum glucose and HbA1c. 
b) To evaluate the association of increased fructosamine levels with the incidence of acute 
myocardial infarction and all-cause mortality. 
c) To evaluate the association of low fructosamine levels and mortality in a population without 
diagnosed diabetes. 
d) To evaluate the long-term prediagnostic development in metabolic risk indicators, including 
fructosamine, before a diagnosis of type 2 diabetes.
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MATERIALS & METHODS 
 
 
THE AMORIS COHORT 
All papers in this thesis were based on 
subjects from the AMORIS (Apolipoprotein-
related MOrtality RISk) cohort that has been 
described extensively elsewhere.44,124 This 
cohort included 812,073 subjects (49% men 
and 51% women) with a mean age of 42.6 
years at the first health examination during 
1985-1996. The majority of the cohort 
subjects was living in Stockholm County, 
Sweden, at the time of inclusion and the sex, 
socioeconomic and ethnic distribution of the 
cohort is representative to that of the general 
Stockholm population in 1990.124  
Reasons for referral  
All subjects had a health examination with 
blood sampling because either they were out- 
patients or they attended a routine part of 
 
health check-ups through occupational health 
care. Pay codes indicated the referral reason 
for the blood sampling. In this thesis, a core 
population, those with available glucose 
measurement, was utilized (n=551,768). In 
this population, three pay codes were used for 
the majority (77%) of the subjects; health 
check-up paid by the employer (34%), health 
check-up paid by the Swedish Social 
Insurance Agency (SSIA) (22%) and referral 
by general practitioners (21%). The reasons 
for the remaining visits (24%) were for the 
purpose of validation or were unknown. 
Subject characteristics of demographic, 
socioeconomic and biomedical factors were 
similar for all three types of pay codes 
(Table 1). 
Table 1. Baseline Characteristics of subjects stratified by referral code 
 Health check-
up (paid by 
employer) 
Health check-up 
(paid by SSIAa) 
Referral by 
physician 
Unknown referral 
reason 
N 185,378 121,370 113,652 123,562 
Age (years) 42 43 48 46 
Fasting 48% 42% 48% 38% 
Female 40% 45% 56% 44% 
Low socioeconomic status 44% 48% 37% 44% 
High socioeconomic status 49% 46% 37% 49% 
BMI (kg/m2) 24.4 24.8 24.1 24.4 
Serum glucose (mmol/L) 4.9 4.9 5.1 5.0 
Fructosamine (mmol/L) 2.07 2.08 2.08 2.28 
Total cholesterol (mmol/L) 5.4 5.5 5.5 5.7 
Triglycerides (mmol/L) 1.3 1.4 1.3 1.3 
aSwedish Social Insurance Agency 
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Laboratory analyses 
More than 35 million laboratory values, 
including repeated measurements, were 
recorded in subjects of the AMORIS cohort, 
covering more than 500 biomarkers. All 
measurements were done on fresh blood at 
the same laboratory (CALAB, Stockholm, 
Sweden) with a well-documented 
methodology. Several well-established 
chemistry biomarkers among others 
triglycerides, total cholesterol, creatinine and 
serum glucose were part of a standard 
analysis package offered without additional 
cost. In addition, novel analyses were 
included although not requested by the 
referring physician, e.g. markers for 
specification of atherogenic dyslipidemias 
(apoB, apoA and the apoB/apoA-I ratio) and 
fructosamine for indication of glycemic 
exposure. These analyses were not clinically 
recognized as recommended analyses, but the 
CALAB laboratory performed investigations 
on potentially valuable risk markers for future 
use, as they were an international leader and 
frontrunner for the development of health 
screening and automation in laboratory 
practice (Autochemist ®). Hence, the 
fructosamine assay, determined with the 
Nitroblue Tetrazolium Colorimetric 
procedure (NBT), was measured in 456,383 
individuals, with a coverage across many 
different levels of glycemic exposure. Among 
those who had measured fructosamine, 43% 
had at least two repeated measurements at 
different dates and many individuals had 
three or more visits (Table 2). 
 
 
 
Table 2. Biochemistry serum markers commonly measured in the AMORIS cohort and included in the present thesis 
Serum marker N % subjects with 
 ≥1 visit ≥2 visits ≥3 visits ≥4  visits 
Creatinine 575,196 46 25 15 
Cholesterol 574,251 46 25 15 
Triglycerides 572,162 46 25 15 
Glucose 551,768 45 25 15 
Albumin 526,417 45 24 15 
Uric acid 531,347 45 24 15 
Fructosamine 456,383 43 22 13 
Haptoglobin 444,314 42 21 12 
apoB 183,609 31 14 8 
apoA 196,890 30 14 8 
HbA1c (blood) 24,863 47 31 22 
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Associations of fructosamine in the 
AMORIS population 
In almost one million analyses of 
fructosamine performed in 456,383 
individuals in the AMORIS cohort, the levels 
were virtually normal distributed (Gaussian 
distribution) with a mean value and standard 
deviation of 2.09 and 0.29 mmol/L 
respectively. Values below 1.8 mmol/L and 
values above 2.6 mmol/L were uncommon 
(Figure 1). There were only few subjects who 
had values above 4.0 mmol/L or values below 
1.0 mmol/L (<0.4%). On average, men had 
somewhat higher levels compared to women. 
No difference was seen, were the subjects 
fasting or non-fasting (Figure 2). A weak 
positive linear correlation was noted between 
fructosamine and age (r=0.15) and hence 
slightly increased fructosamine was seen by 
increasing age in a sex and fasting adjusted 
linear regression model. Fructosamine 
increased significantly by 0.0033 mmol/L for 
each year the age increased. 
Metabolic blood markers of glycemic, lipid 
related and inflammatory exposure also 
demonstrated significant linear correlations 
with fructosamine and were observed for 
glucose (r=0.53), total cholesterol (r=0.25), 
triglycerides (r=0.25) and albumin (r=0.17) 
(Figure 3). Fructosamine was mainly 
associated with the atherogenic part of 
cholesterol as shown by a positive association 
with apoB and no association with apoA. 
Non-linearity was noted for fructosamine and 
most markers at very low or high levels. 
Nonetheless, in reasonable intervals of each 
marker (99.8 % of all subjects) a positive 
linearity prevailed. Serum albumin, which has 
burdened the potential use of 
fructosamine,3,125-127 was rather uncorrelated 
with fructosamine in the hyperglycemic 
interval.  
        
Figure 1. Distribution of fructosamine in the AMORIS                Figure 2. Cumulative distribution of fructosamine in  
population, compared to an estimated Gaussian distribution.         the AMORIS population. Showed for men, women,                                                 
                                                                                                          fasting subjects and non-fasting subjects respectively
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Figure 3. Relationship between fructosamine (FA) and biochemical serum markers in fasting subjects. Dashed 
line: linear regression in fructosamine range 1.0-4.0 mmol/L. Solid blue line: penalized B-spline with 95% CI 
for the mean. Vertical lines represents thresholds for 0.1%- extremes of the population.  
REGISTER DATA LINKED TO AMORIS  
Loss to follow-up can be an important 
limitation in epidemiological studies. In 
Sweden, there are national health and 
population registers of high quality and 
completeness for hospitalizations, specialized 
outpatient care, dispensed prescriptions of 
medical drugs, migration and mortality. The 
unique Swedish personal identification 
number (PID) enables linkage of research 
studies to these national records. This helps to 
minimize loss to follow-up in 
epidemiological studies using these registers. 
Within the scope of the ethically approved 
(Record number: 2010/1047-31/1) research 
project “Epidemiologic studies of metabolic  
 
factors and inflammation in relation to 
chronic disease”, the CALAB laboratory 
database was linked to 24 registers. These 
included national health registers, quality of 
care registers, national registers of 
socioeconomic data and research cohorts 
(Table 3). During the period, 1985-2012, 
there were 153,820 deaths (18.9%), 175,334 
cancer diagnoses (21.6%) and 4.5 million 
hospitalizations recorded for the cohort.124 
Furthermore, about 48,000 new cases of T2D 
occurred in the sub population with serum 
glucose measured during this period. 
The registers linked to the AMORIS cohort 
that are essential for this thesis are briefly 
described below. 
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Table 3. Important register linkages to the AMORIS cohort 
Category Data Source Linkage period 
CALAB blood sampling AMORIS 1985-1996 
National Health Register Inpatient Care 1964-2011 
 Specialized Outpatient Care 2001-2011 
 Cause of death 1985-2011 
 Prescribed drug128 2005-2012 
 Medical Births (MFR) 1973-2011 
Migration, Social, Family Migration 1968-2012 
 Census/LISA 1970-2010 
Lifestyle National surveys and research 
cohorts at Karolinska institutet 
1963-2012 
Quality of Care National Diabetes Registry (NDR) 1996-2012 
 SWEDHEART 1991-2012 
National patient register 
The Swedish National Patient Register started 
regionally in 1964 and has national coverage 
since 1987.129 Stockholm County was one of 
the first regions with a patient register starting 
in 1970. Initially, only inpatient care visits 
were recorded, however from 2001 the 
register also records all specialized outpatient 
care visits. The Swedish National Board of 
Health and Welfare performs regular updates 
of this register, which has coverage of more 
than 99% of all somatic and psychiatric 
hospital discharges including patient data, 
geographical data, administrative data of the 
hospital stay, and medical data. The 
diagnoses are defined by codes standardized 
in the International Classification of Diseases 
(ICD). 
National cause of death register 
The Swedish Cause of Death Register started 
in 1961 and comprise both specific causes of 
death and date of death for all Swedish 
citizens at the time of death, regardless if 
death occurred in Sweden or elsewhere. The 
Cause of Death Register use coding in 
accordance with the ICD. 
National diabetes registry 
The Swedish National Diabetes Registry 
(NDR) started to include patients with DM in 
1996. In the beginning, the case coverage was 
limited but today it roughly includes almost 
90 % of all Swedish diabetes patients. The 
estimated coverage differs across Swedish 
County Councils and some counties estimate 
having full coverage.130 The NDR is an 
important source for DM research in Sweden 
and includes information about type of DM, 
year of diagnosis, current glycemic and lipid 
levels and examinations and assessments of 
the retina. Through this register, it is possible 
to identify prevalent as well as incident DM 
patients.  
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Lifestyle 
Lifestyle and comorbidity factors such as 
smoking status, anthropometric 
measurements, self-reported diseases, 
including DM and hypertension, were 
obtained through linkages with research 
cohorts, setup and maintained by research 
groups at Karolinska institutet. This includes 
the WOLF study,131 the Stockholm 60-years 
old cohort,132 the Swedish Twin Registry,133 
Sollentuna Prevention Program,134,135 and the 
COSM/SMC nutritional cohorts.136 In the 
scope of this thesis, the author integrated 
information on important covariates from 
several of those registers (e.g. smoking, 
hypertension and BMI) in a standardized 
covariate database. This database enabled and 
simplified the inclusion of potential 
confounders in the analyses. 
Migration and social factors 
The Migration Register maintained and 
updated by Statistics Sweden (Statistiska 
centralbyrån, SCB) provided dates for 
immigration and emigration. Those dates 
enabled censoring at emigration out of 
Sweden and consequently lost to follow-up. 
Socioeconomic status was derived from 
occupational codes recorded in the national 
censuses from 1970 to 1990 and was 
available for nearly all subjects in the 
AMORIS cohort. Information on occupation 
and education was also available from the 
“Longitudinal integration database for health 
insurance and labour market studies” (LISA) 
in 1990 and later.
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STUDY METHODS 
Short descriptions of the methods, which 
were used in the four papers are given below. 
These are also summarized in Appendix 
Table 1. 
Study I 
Participants 
The study population was identified from the 
AMORIS cohort and comprised those 
subjects who had glucose, fructosamine and 
HbA1c measured at the same examination 
date during the period 1985-1996 (n=10,987). 
In the study population, 53% were women. 
Exposure 
We identified subgroups of glycemic 
exposure based on ADA guidelines or on 
documented diabetes diagnosis primarily 
supplied by the National Diabetes Register 
(NDR). We defined five groups; normal 
glucose tolerance, prediabetes, newly 
diagnosed T2D (NewT2D, through the 
AMORIS blood sample), previously 
diagnosed T2D (DiagT2D, documented in 
register) and T1D (from register or less than 
30 years and diabetes diagnostic levels at the 
AMORIS blood sample). 
Statistical analysis 
We estimated Pearson linear correlation 
coefficients for combinations of 
fructosamine, glucose and HbA1c and 
analyzed correlations in fasting as well as 
non-fasting conditions. Furthermore, we 
presented correlation coefficients overall and 
within the glycemic exposure subgroups. 
Partial correlations were estimated to account 
for potential confounder influence on the 
estimated correlations. Sensitivity and 
specificity for diabetes at defined cut-off 
values for fructosamine and area under the 
receiving operator curve (AUC-ROC) were 
estimated by use of a “gold standard” for 
diabetes diagnosis based on fasting glucose 
and HbA1c (ADA). In a subset with at least 
three repeated measurements on all three 
markers available within one year, a 
longitudinal analysis was conducted to 
evaluate the associations progressively. 
Study II 
Participants 
In the AMORIS cohort, all subjects who were 
30 years or older and who had fructosamine, 
glucose, total cholesterol, triglycerides and 
serum albumin measured simultaneously 
during the baseline period 1985-1996 and had 
no previous history of CVD were included in 
the study population (n=338,443; 178,947 
men and 159,496 women). 
Exposure and other potential 
confounders 
We categorized fructosamine levels in 
accordance with clinically relevant sub-
groups based on glycemic exposure levels 
observed for glucose, HbA1c and 
fructosamine in study I (Table 4).137 
Table 4. Classifications of fructosamine levels. 
Fructosamine (mmol/L) Classified as: 
< 1.78 Lowest 5% 
1.78-2.29 Normal glucose (ref) 
2.30-2.59 Prediabetes 
2.60-2.69 Well-controlled T2D 
≥ 2.70 Poorly controlled T2D 
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Outcome and follow-up 
The primary outcome in this study was 
incident myocardial infarction (MI). Non-
fatal MI and death from coronary heart 
disease (CHD) were included in the primary 
outcome. Secondary outcome was all-cause 
mortality. We obtained outcomes from 
linkage to the national inpatient register and 
cause of death register respectively. Subjects 
were followed from the first examination 
(1985-1996) until first MI, death, emigration 
or the end of the study (December 31st, 
2011), whichever occurred first. 
Statistical analysis 
We used Cox proportional hazard 
regression,138 with attained diurnal age as the 
underlying timescale, to estimate hazard 
ratios with 95% confidence intervals for MI 
and all-cause mortality respectively 
comparing exposure categories of 
fructosamine to the reference group. The 
analysis allowed for updating exposure and 
other covariates whenever repeated 
measurements became available (i.e. repeated 
measurements). To disentangle the 
independent effect of fructosamine, we tested 
four models. Model 1: sex, age and calendar 
time; Model 2: Model 1+ total cholesterol, 
triglycerides and serum albumin; Model 3: 
Model 2+social class; Model 4: Model 2+ 
glucose. In addition, we compared three 
measures of glycemic exposure (i.e. fasting 
glucose, HbA1c and fructosamine) with 
respect to risk prediction of the study 
outcomes. 
 
Study III 
Participants 
All subjects who were fasting and had 
simultaneous measurements of fructosamine, 
glucose, total cholesterol, triglycerides, 
albumin, creatinine, uric acid and haptoglobin 
in the baseline period of 1985-1996              
(n =215,011; 47% women). Patients with 
diabetes were excluded at baseline and 
censored whenever a diagnosis became 
known during the follow-up period.  
Exposure and other potential 
confounders 
The 10% lowest ordered fructosamine 
constituted the exposure of interest. Ordered 
levels between 10 and 90% established the 
reference category and the highest 10% 
constituted an ‘other’ category. Potential 
confounders included metabolic biomarkers 
(i.e. total cholesterol, triglycerides, albumin, 
creatinine, uric acid and haptoglobin). 
Sensitivity analyses included smoking 
(ever/never), BMI and reverse causation of 
malignancies (by linkage to the National 
Cancer Register).  
Outcome and follow-up 
We obtained information on all-cause 
mortality and cause-specific mortality 
respectively from the national cause of death 
register. We defined five categories of cause-
specific deaths: 1) cardiovascular, 2) cancer, 
3) lung cancer/COPD, 4) infections and 5) all 
other deaths. Subjects were followed from the 
baseline examination (1985-1996) until death, 
emigration or the end of the study (December 
31st, 2011), whichever occurred first. 
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Statistical analysis 
Cox regression models138 were constructed by 
using cubic restricted splines of fructosamine 
and fasting glucose respectively and diurnal 
age as the underlying timescale. Hence, we 
depicted a continuous risk curve of HRs with 
95% CI over the complete range of respective 
marker. Further, the lowest ordered 10% of 
fructosamine was compared to the reference 
group and hazard ratios with 95% CI were 
estimated for all study outcomes.  
 
Study IV 
Participants 
All individuals who had a fasting glucose 
measurement in the baseline period (1985-
1996) were included in the study population 
except for those with a diabetes diagnosis at 
baseline, either documented, self-reported or 
diagnosed by the CALAB fasting blood 
glucose (≥7.0 mmol/L) (n=296,439).  
Metabolic risk factors 
Potential risk factors investigated in this study 
included glucose, fructosamine, haptoglobin, 
uric acid, triglycerides, total cholesterol, BMI, 
apoB, apoA-I and the apoB/apoA-I ratio. 
Outcome and follow-up 
The follow-up continued from the baseline 
examination until a diagnosis of T2D (the 
event of interest), emigration, death or June 
30th 2012. The diagnoses were obtained from 
the national diabetes register, the national 
patient register, the national prescribed drug 
register, the CALAB repeated blood samples 
and self-reports. The earliest record from any 
of those registers constituted type of 
diagnosis and year of diagnosis in the 
analysis. 
Nested case-control sample 
To facilitate the analyses of trajectories, we 
constructed a nested case-control sample 
from the study population. New cases of T2D 
during the follow-up period were matched to 
five controls by sex, age group and calendar 
time in an incidence density sampling 
approach.139 Number of years (NoY) from the 
first measurement of fasting glucose and the 
diagnosis/control selection was calculated. 
Statistical analysis 
In the study population, hazard ratios 
accounting for one standard deviation of 
respective risk factor (95% CI) were 
estimated with Cox PH regression.138 In 
addition, hyperglycemic cut-offs for 
fructosamine were set and hazard ratios 
estimated. We estimated absolute 10- and 20- 
year risks stratified on sex, age, BMI, 
triglycerides and glucose through logistic 
regression models. Weighted mean values 
and 95% CI were calculated for all risk 
markers by each NoY and trajectories were 
described graphically for respective factor. 
We used the distribution of sex, age group 
and calendar time of the full nested case-
control sample as reference population in the 
weighting procedure.
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RESULTS 
  
STUDY I 
Subject characteristics 
The study included 10,987 subjects, whereof 
47% were males, with a wide range of 
glycemic exposure. Out of those, 7,591 had 
normal glucose tolerance (n=5,714) or were 
in a pre-diabetes state (n=1,877). Subjects 
with T2D were on average 20 years older  
 
 
compared to subjects with T1D (Table 5). For 
either newly diagnosed T2D or previously 
diagnosed T2D, the mean levels of 
fructosamine, serum glucose and HbA1c 
were similar in both fasting and non-fasting 
subjects. Subjects with T1D had on average 
higher levels of fructosamine, HbA1c and 
serum glucose. 
 
Table 5. Characteristics of individuals with diabetes in the study population (Study I) 
 NewT2D DiagnosedT2D  T1D 
 Fasting  Non-fast Fasting Non-fast Fasting Non-fast 
N 759 497 825 1,035 88 192 
% of pop 7% 5% 8% 9% 1% 2% 
Female sex 33% 35% 37% 41% 44% 46% 
Age (mean) 61 (12)  62 (12)  60(11)  62 (11)  41 (11)  40 (13)  
Age (years)       
-30 0 0 1 1 19 46 
30-49 131 73 151 155 47 93 
50-69 432 273 514 600 22 52 
70- 196 151 159 279 0 1 
BMI      29 (4.7) 29 (5.3) 29 (5.0) 28 (5.0) 26 (4.6) 26 (4.3) 
Fructosamine 2.62 (0.52) 2.83 (0.54) 2.71 (0.58) 2.77 (0.55) 2.93 (0.62) 3.11 (0.63) 
HbA1c 6.93 (1.66) 7.92 (1.53) 7.21 (1.77) 7.41 (1.70) 7.62 (1.58) 7.88 (1.56) 
Glucose  9.55 (3.01) 11.1 (4.20) 9.61 (3.60) 10.5 (4.60) 11.3 (5.33) 10.5 (5.73) 
Albumin  42.9 (2.6) 42.7 (2.9) 42.7 (3.1) 42.8 (2.9) 42.3 (3.4) 42.9 (3.2) 
Triglycerides 2.30 (1.80) 2.56 (2.43) 2.32 (2.30) 2.24 (1.98) 1.61 (1.31) 1.27 (0.91) 
Total cholesterol 6.07 (1.20) 5.98 (1.26) 6.01 (1.47) 5.96 (1.37) 5.45 (1.32) 5.42 (1.48) 
LDL-C  3.83 (1.15) 3.80 (1.07) 3.71 (1.14) 3.71 (1.13) 3.36 (1.28) 3.31 (1.15) 
HDL-C  1.27 (0.44) 1.23 (0.39) 1.32 (0.45) 1.30 (0.40) 1.58 (0.58) 1.60 (0.43) 
ApoB  1.40 (0.41) 1.40 (0.48) 1.39 (0.48) 1.31 (0.42) 1.27 (0.61) 1.04 (0.37) 
ApoA-I  1.38 (0.23) 1.38 (0.24) 1.39 (0.24) 1.38 (0.21) 1.46 (0.26) 1.46 (0.23) 
ApoB/ApoA   1.04 (0.34) 1.03 (0.31) 1.03 (0.40) 0.97 (0.31) 0.88 (0.41) 0.73 (0.27) 
Creatinine  85.7 (16.3) 86.7 (19.0) 86.4 (19.7) 89.4 (35.7) 85.2 (23.8) 82.2 (18.7) 
eGFR 79.3 (16.3) 77.5 (17.2) 79.3 (17.1) 76.0 (19.4) 91.8 (20.3) 92.4 (17.8) 
Education  35% 35%  37%  36%  20% 21% 
Sweden born  79% 76% 77% 81% 86% 90% 
B-C, Workers 14%  13% 18%  17%  19% 17% 
History, CVD 7% 6%  13%  14%  7% 3% 
History, cancer 7% 8% 7% 8% 2% 3% 
CKD  14% 16% 12% 21% 9% 7% 
Anemia 0.9% 0.2% 1.8% 2.5% 2.3% 1.0% 
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Cross-sectional correlations between 
metabolic biomarkers 
The linear correlation between fructosamine 
and HbA1c in fasting subjects was r=0.75, 
r=0.75 and r=0.67 in NewT2D, DiagT2D and 
T1D respectively (Figure 4). In non-fasting 
subjects with T2D, fructosamine and HbA1c 
correlated somewhat less. Adding a non-
linear component in the correlation analysis 
increased the correlations marginally for 
DiagT2D (r=0.76) but not for NewT2D. The 
correlation between fructosamine and HbA1c  
was much lower in subjects with prediabetes 
(r=0.11) and was null in subjects with normal 
glucose tolerance (not shown). In 
comparison, fructosamine correlated higher to 
total cholesterol (r=0.31, p<0.001), 
triglycerides (r=0.18, p<0.001) and albumin 
(r=0.23, p<0.001) in subjects with normal 
glucose tolerance compared to fasting glucose 
(r=0.12, p<0.001) and HbA1c (r=-0.01) 
respectively (post publication analysis). 
 
  
Figure 4. Scatterplots of fructosamine and HbA1c by type of diabetes and fasting status. Pearson linear correlation 
coefficients (r), linear regression curve (blue dashed line) and smoothed penalized splines (solid red line) are indicated 
in respective graphs. Diagnostic diabetes cut-off for HbA1c (6.5%) according to guidelines and potential cut-off for 
fructosamine (2.5 mmol/L) are indicated. 
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Longitudinal analysis of changes in 
simultaneously measured biomarkers 
To evaluate the correlation between the three 
measurements of glycemic exposure over 
time, we identified and restricted to those 
subjects who had simultaneous measurements 
of all three biomarkers (fructosamine, HbA1c 
and glucose) at an index examination and in 
two consecutive time windows during one 
year. For those who had increased their 
glucose after an average of 290 days, 
fructosamine and HbA1c had increased in 
parallel (Figure 5). Correspondingly, for 
those who had decreased their glucose levels 
after 290 days, also had decreased their levels 
of fructosamine and HbA1c respectively. 
Newly diagnosed as well as long-standing 
T2D were similar in this development.  
 
 
Figure 5. Mean values of fructosamine, HbA1c and glucose at the index examination and within two time 
windows in the following year. 
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STUDY II 
Study participants’ characteristics 
The study included 338,443 subjects. Men 
(53%) and women were about 48-50 years on 
average at baseline, i.e. the time of the first 
blood sampling. About 60% were fasting at 
the baseline measurement (Table 6). On 
average, men had higher fructosamine 
compared to women, 2.13 vs. 2.05 mmol/L 
(not shown). Consequently, proportionally 
more men than women were in the higher 
fructosamine categories (Table 6). 
Furthermore, subjects with elevated 
fructosamine were older on average  
compared to subjects with lower levels of 
fructosamine. Triglycerides and glucose were 
positively associated with the fructosamine 
categories. Total cholesterol was similar in all 
groups above 2.30 mmol/L. 
Event rates of MI and death 
We observed 21,526 incident MIs and 73,458 
deaths during the follow-up. The event rate of 
MI was higher among men (44 cases/10,000 
person years) than among women (24 
cases/10,000 person years). The sex 
difference in mortality was less pronounced 
than that observed for incidence of MI. 
 
Table 6. Subject characteristics at first visit – stratified by fructosamine levels. 
 Fructosamine levels (mmol/L) 
 <1.78 1.78-2.29 2.30-2.59 2.60-2.69 ≥2.70 
n, subjects 18,371 271,832 39,246 2,335 5,305 
% with repeated measures 43% 45% 37% 43% 54% 
Female 64% 48% 35% 33% 31% 
Fasting (%) 60% 58% 60% 61% 58% 
Age inclusion, years (range) 47 (39-54) 49 (40-56) 52 (42-60) 55 (46-64) 58 (49-65) 
Socioeconomic status      
   Low 49% 43% 37% 39% 39% 
   High 44% 50% 53% 47% 44% 
   Not gainfully employed 7% 7% 10% 14% 17% 
Fructosamine (mmol/L) 1.7 (0.1) 2.1 (0.1) 2.4 (0.1) 2.6 (0.0) 3.2 (0.5) 
Glucose (mmol/L) 4.7 (0.7) 4.9 (0.7) 5.2 (1.2) 6.4 (2.2) 11.0 (4.8) 
Total cholesterol (mmol/L) 5.2 (1.0) 5.7 (1.1) 6.3 (1.2) 6.5 (1.4) 6.3 (1.6) 
Triglycerides (mmol/L) 1.2 (0.8) 1.3 (0.9) 1.7 (1.4) 2.4 (2.4) 2.9 (3.4) 
Albumin (g/L) 40.8 (3.0) 42.8 (2.7) 43.7 (2.8) 43.3 (3.1) 42.4 (3.1) 
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Association of fructosamine and 
incident MI and all-cause mortality 
There was a clear positive association of 
fructosamine levels and incidence of MI 
(Figure 6) as well as with all-cause mortality 
(Figure 7). In the model adjusted for sex, age, 
fasting status and calendar time there was a 
slightly increased hazard for MI in the 
prediabetes group compared to the reference 
group and the hazard ratio increased with 
higher fructosamine and was highest in the 
poorly controlled diabetes group (HR=2.9, 
95% CI 2.7-3.1). Further adjustment for 
potential confounders of the association 
between fructosamine and MI incidence (i.e. 
total cholesterol, triglycerides, albumin and 
glucose) retained the hazard ratio increased 
(Figure 6). For all-cause mortality we noted 
the same risk pattern as was noted for 
incident MI, although the magnitude of the 
HRs was less (Model 1 HR= 2.3 (95% CI 
2.2-2.4)) (Figure 7). Furthermore, there was 
an increased HR for all-cause mortality when 
comparing ‘prediabetes’ and ‘Low5%’ 
respectively with the referents even when 
glucose was included in the multivariate 
models.  
 
 
Figure 6. Incident Myocardial Infarction and CHD death, hazard ratios with 95% CI comparing fructosamine in 
clinical important groups to normal range One subject eligible for counting in multiple fructosamine categories. 
Vertical dotted lines indicate boundaries for the categories of fructosamine. 
Håkan Malmström   
42 
 
  
Figure 7. All-cause mortality, hazard ratios with 95% confidence intervals comparing fructosamine in clinical 
important groups to normal range. One subject eligible for counting in multiple fructosamine categories. 
Vertical dotted lines indicate boundaries for the categories of fructosamine. 
Comparative analysis of fructosamine, 
HbA1c and fasting glucose regarding 
the association to MI and death 
In a subset of the study population, HbA1c 
was measured (n=9,746) and we categorized 
those subjects with respect to glycemic 
exposure. Fructosamine and HbA1c were 
similar in risk predictions for MI and all-
cause mortality in prediabetes, controlled 
T2D and poorly controlled T2D respectively 
(Figure 8). There was an indication of higher 
mortality in the prediabetes group estimated 
by fructosamine compared to when estimated 
by HbA1c. In the prediabetes group, the mean 
level was 2.43 mmol/L and 6.01% for 
fructosamine and HbA1c respectively. 
Fasting glucose demonstrated constantly 
lower HRs as compared to fructosamine and 
HbA1c. The increased HRs for all-cause 
mortality were found for fructosamine even 
after adjustment for HbA1c. 
 
Figure 8. Hazard ratios for MI and all-cause mortality 
in categories of fructosamine, HbA1c and fasting 
glucose respectively.
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STUDY III 
Study participants’ characteristics 
There were 215,011 individuals included in 
the study and about half of these were 
women. Individuals characterized by low 
fructosamine were younger on average 
compared to individuals in the reference 
group (Table 7). In addition, the proportion 
with low socioeconomic status was higher.  
The intersection of low fructosamine and low 
glucose was 15%. Biomarkers of lipid related 
exposure (including apo-B and apo-A-I (not 
shown)) indicated healthier levels in the 
lowest fructosamine group compared to 
medium and higher values. Serum 
haptoglobin was higher in the low 
fructosamine group compared to the groups 
with medium or high levels. 
Table 7. Subject characteristics of 215,011 individuals with fasting measurements of biomarkers presented in total and 
by distribution of baseline fructosamine (<10%, 10-90% and >90%). 
 Baseline fructosamine  
 Low 10% Medium High 10% ALL 
Subjects, n 21,377 173,153 20,481 215,011 
Women (%) 47% 47% 47% 47% 
Age at baseline (sd) 43 (14) 46 (14) 50 (14) 46 (14) 
Low socioeconomic status 47% 43% 39% 43% 
Low 10% Glucose (%) 15% 11% 8% 11% 
High 10% Glucose (%) 5% 8% 16% 8% 
S-Fructosamine (mmol/L) 1.72 (0.1) 2.07 (0.1) 2.40 (0.1) 2.07 (0.2) 
S-Glucose (mmol/L) 4.66 (0.6) 4.77 (0.6) 4.95 (0.7) 4.77 (0.6) 
Triglycerides (mmol/L) 1.11 (0.7) 1.19 (0.8) 1.49 (1.2) 1.21 (0.8) 
Total Cholesterol (mmol/L) 5.08 (1.1) 5.59 (1.1) 6.28 (1.3) 5.60 (1.1) 
Albumin (g/L) 41.2 (3.0) 42.6 (2.7) 43.5 (2.8) 42.6 (2.8) 
S-Uric acid (µmol/L) 276 (67.3) 286 (69.3) 304 (75.8) 287 (70.0) 
Creatinine (µmol/L) 78.4 (13.7) 81.1 (14.2) 84.1 (15.4) 81.2 (14.4) 
S-Haptoglobin (g/L) 1.12 (0.4) 1.05 (0.3) 1.01 (0.3) 1.05 (0.3) 
Ever smokers (%)a 36% 27% 21% 27% 
a in a subset of 43,313 subjects (93% women)     
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All-cause mortality across the 
fructosamine continuum 
The mortality was lowest in subjects with 
fructosamine levels of 2.20-2.30 mmol/L 
(Figure 9). Low and intermediate levels of 
fructosamine were associated with increased 
mortality. After adjusting for a set of potential 
confounders, including haptoglobin, the 
increased mortality at lower fructosamine 
levels was attenuated. Haptoglobin unaided, 
accounted for a major part of this reduction in 
hazard ratios. 
 
Low fructosamine and Cause specific 
mortality  
The cause-specific mortality, i.e. 
cardiovascular-, cancer-, or all other reasons 
(not including infection) increased in the low 
fructosamine group vs. the medium 
fructosamine group (Table 8). In particular, 
mortality in lung cancer or chronic 
obstructive pulmonary disease (COPD) was 
significantly increased in those with low 
fructosamine (HR=1.42 (95% CI 1.28-1.58) 
in adjusted model 2). The major causes of 
death were otherwise proportionally 
comparable regardless of fructosamine 
category. 
  
Figure 9. Hazard ratios for all-cause mortality across levels of fasting fructosamine. Model 1 is adjusted for sex, 
age, social class and calendar period. Model 2 additionally adjusted for total cholesterol, triglycerides, albumin, 
creatinine, uric acid and haptoglobin. Proportions of subjects concerned are displayed by vertical dotted lines.
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Table 8. Hazard ratios for subjects with low fructosamine (1st decile) vs referent fructosamine (medium 10-90%) by 
cause of death categories. 
  Model 1 Model 2 
Cause of death No. of deaths† Hazard ratios (95% confidence interval) 
   CVD 15,363 (1,413) 1.08 (1.02-1.15) 1.06 (0.99-1.12) 
   Cancer 13,781 (1,557) 1.29 (1.21-1.36) 1.15 (1.09-1.22) 
   Infections 1,341 (129) 1.15 (0.96-1.38) 0.99 (0.82-1.20) 
   Lung cancer/COPD 3,566 (522) 1.70 (1.55-1.86) 1.42 (1.28-1.58) 
   All other causes  9,790 (1,037) 1.21 (1.13-1.29) 1.12 (1.04-1.20) 
   All causes 41,388(4,281) 1.20 (1.16-1.24) 1.11 (1.07-1.15) 
Model 1: sex, age, socioeconomic status and calendar period; Model 2: Model 1 + triglycerides, total cholesterol,  
albumin, uric acid, creatinine and haptoglobin; † Number of deaths (n of deaths in lowest fructosamine decile) 
 
 
 
Influence of smoking and 
inflammation in the relation between 
low fructosamine and mortality 
In sensitivity analyses (not shown), we 
observed a reduction of the hazard ratio for 
all-cause mortality in the lowest 10% of 
fructosamine vs. the reference group when we 
adjusted for smoking status (ever/never). The 
reduction extended to almost 25%. In a 
haptoglobin stratified analysis, we showed 
similar fructosamine related hazard ratios 
across all quartiles of haptoglobin in model 1 
and none or minor reduction of those hazard 
ratios when adjusted for haptoglobin. 
Additional sensitivity analyses were 
performed to- a) adjust for any reverse 
causation from cancer b) adjust for any 
influence regarding body mass index and c) 
adjust for an extensive set of biomarkers 
including apolipoproteins, sodium, potassium 
and liver related markers. None of these 
analyses substantially differed from the 
results of the main analyses.
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STUDY IV 
Study participant characteristics 
There were 296,436 individuals included in 
the study population. On average, the study 
subjects were 44.8 years at the baseline 
examination, all were fasting and 47% of 
them were women.  
Characteristics of T2D cases 
The mean age of a T2D diagnosis was 63.2 
years. The T2D cases were more frequently 
of low socioeconomic status compared to 
controls. Furthermore, the T2D cases had 
higher BMI and higher levels of most of the 
biomarkers related to glycemic, lipid and 
inflammatory exposures, except for apo A-I, 
which was lower compared to the controls. 
Associations of metabolic risk 
markers and diagnosis of T2D 
Markers of glycemic, lipid and inflammatory 
exposure respectively were all associated 
with the incidence of T2D, in sex, age and 
calendar time adjusted models. Most markers 
showed an association after adjustments for 
triglycerides, glucose and uric acid 
respectively. The risk of T2D was increased 
in two defined categories of pre-diagnostic 
fructosamine after adjustment for total 
cholesterol, fasting triglycerides and fasting 
glucose. The adjusted risk was 33% higher 
for those with fasting fructosamine between 
2.46 and 2.59 mmol/L compared to those 
below 2.33 mmol/L (Table 9). 
Trajectories describing the 
development of metabolic markers 
before T2D 
We identified 28,235 new cases of T2D 
during the follow-up period. In graphically 
described trajectories, mean values of several 
biomarkers were increased in T2D subjects 
vs. controls more than 20 years before the 
diagnosis/control selection. BMI, fasting 
glucose and triglycerides were below clinical 
cut-offs for obesity, hyperglycemia and 
hypertriglyceridemia respectively, at 20 years 
before diagnosis, yet at higher levels 
compared to controls (Figure 10). 
Fructosamine was different in T2D cases 
compared to controls at 15 years before the 
diagnosis/control selection and this difference 
increased closer to diagnosis of the cases. In 
addition, other markers including uric acid, 
haptoglobin and apoB/apoA-I ratio were 
increased in cases compared to controls long 
before the diagnosis. Accelerated differences 
between cases and controls over time, 
primarily appeared for glucose and 
fructosamine, while more constant 
differences were observed for triglycerides, 
BMI, uric acid and haptoglobin.
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Figure 10. 25-year trajectories of fasting glucose, fructosamine, triglycerides and BMI in T2D cases and controls 
respectively. 
 
Prediction of long-term risk of T2D 
The observed 20-year risk of T2D was 8.1% 
in the study population. In both men and 
women, the risk increased considerably with 
higher BMI (Figure 11). Elevated blood lipids 
in the form of triglycerides ≥1.4 mmol/L (124 
mg/dL) approximately doubled up the risk of 
T2D independently of BMI. With a BMI of 
≥30 kg/m2, triglycerides ≥ 1.4 mmol/L and a 
fasting glucose ≥ 5.6 mmol/L (100 mg/dL) 
the estimated 20-year risk of T2D was 64% 
and 70% in men and women aged 40-49 
years respectively. The risk remained high in 
those individuals even at normal glucose 
levels and was 21% and 18% in men and 
women respectively.
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  Fasting triglycerides (mmol/L) 
  <1.4 mmol/L  ≥1.4 mmol/L 
 ≥30 9 12 21 35 Men 19 24 38 55 
BMI 25-30 3 4 7 13 30-39 years 6 8 14 25 
 <25 1 2 3 6  3 4 7 13 
           
 ≥30 12 13 25 47 Men 21 23 40 64 
BMI 25-30 5 6 12 26 40-49 years 10 11 21 41 
 <25 2 3 6 13  4 5 10 23 
           
 ≥30 6 10 17 45 Women 15 23 36 69 
BMI 25-30 3 6 10 31 30-39 years 9 14 24 55 
 <25 1 1 3 10  2 4 7 22 
           
 ≥30 8 14 24 48 Women 18 28 44 70 
BMI 25-30 4 6 12 29 40-49 years 9 14 25 50 
 <25 1 2 5 12  3 6 11 26 
  <4.5 4.5-4.9 5.0-5.5 5.6-6.9  <4.5 4.5-4.9 5.0-5.5 5.6-6.9 
  Fasting glucose (mmol/L)  Fasting glucose (mmol/L) 
           
Figure 11.  Estimated 20-year absolute risk of T2D based on sex, age, BMI, fasting glucose and 
triglycerides. Green color (risk <5%), yellow color (risk 5-20%), red color (risk ≥ 20%). BMI: kg/m2.
 
 
Table 9. Adjusted hazard ratios (95% CI) of baseline fasting fructosamine and incident T2D. Categories correspond to 
< FSG 5.6 mmol/L, FSG 5.6-6.0 mmol/L, 6.1-7.0 mmol/L and AMORIS diabetes cut-off for fructosamine. Based on 
202,183 subjects and 18,285 incident T2D cases. 
Fructosamine (mmol/L) Model 1a Model 2b  Model 3c  
<2.33 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2.33-2.45 1.35 (1.28-1.42) 1.20 (1.14-1.26) 1.08 (1.02-1.13) 
2.46-2.59 1.77 (1.64-1.91) 1.33 (1.23-1.44) 1.16 (1.08-1.26) 
≥2.60 2.45 (2.20-2.74) 1.38 (1.23-1.54) 1.23 (1.10-1.38) 
a adjusted for sex and age; b adjusted for sex, age, triglycerides, total cholesterol; c adjusted for sex, age, triglycerides, 
total cholesterol and fasting glucose 
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DISCUSSION 
MAIN FINDINGS 
In a large population, we have demonstrated a 
strong linear association concerning 
measurements of fructosamine and the major 
glycemic determining biomarkers glucose 
and HbA1c. We showed a curvilinear 
correlation in those measurements, where 
states of hyperglycemia or diagnosed diabetes 
of either type 1 or type 2 constituted 
thresholds. As expected, changes in glucose 
over time were reflected in similar parallel 
increases or decreases in fructosamine and 
HbA1c. Fructosamine levels may 
differentiate subjects with and without 
hyperglycemia. Measurements of 
fructosamine correlates well with glucose 
levels in the hyperglycemic range and has the 
clinical advantage that fasting is not a 
prerequisite to obtain reliable values. 
Elevated levels of fructosamine were 
associated with the incidence of acute 
myocardial infarction and mortality in the 
total study population. The excess risks for 
these outcomes were largely the same for 
either fructosamine, fasting glucose or 
HbA1c. One would presume that the 
molecular mechanism that causes damage 
would be the same or similar for all these 
three markers and such a mechanism have 
been discussed previously. The molecular 
mechanisms underlying the mortality-
increasing associations of low levels of 
fructosamine, also pointed out previously,105 
remain to be explained in detail, yet some of  
these associations could be due to 
concomitant smoking and inflammatory 
mechanisms.140-143 
Lastly, up to 25 years prior to diagnoses, 
individuals who developed T2D differed from 
those who did not with regard to several 
factors, among them fasting glucose, 
triglycerides and BMI. A difference in 
fructosamine between T2D cases and controls 
appeared more closely to the diabetes 
diagnosis than when a difference in fasting 
glucose was observed. Thus, our results 
suggest that increased fructosamine compared 
to a reference population may appear about 
15 years before the diagnosis of T2D. The 
increased risk of elevated fructosamine at pre-
diagnostic levels was low as compared to 
glucose, triglycerides and BMI, yet present 
and of importance as a marker of forthcoming 
risk. Altogether, these findings of higher 
values of fasting glucose, fructosamine, 
triglycerides and BMI in cases compared to 
controls may raise consideration about when 
and why T2D starts to develop. The major 
findings of this thesis may substantiate the 
utility of fructosamine as a glycemic 
determinant in clinical practice and 
epidemiological research. 
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METHODOLOGICAL REFLECTIONS 
Selection bias 
If the selection process of individuals into the 
study is associated with the outcome and/or 
the exposure, bias may arise.144 Then the 
exposure-outcome relationship may no longer 
be representative to that of the target 
population from which the study population 
arose.145  
Fructosamine, the main exposure of interest 
in this thesis, was included in a standard 
package of analyses that was a no-fee test 
offered by the CALAB laboratory. Hence, 
any suspicions of disease is not likely to 
influence the recording of fructosamine and 
the selection of subjects into the different 
studies of this thesis. Thus, we assume that 
the selection process into the studies should 
have been similar for cases and non-cases 
(Study II-IV). 
Any loss-to follow-up affected by exposure 
or disease could bias the epidemiological 
measures. By use of national event registers 
(Study II-IV) and emigration register, there 
should be a very small loss to follow-up in 
the studies of this thesis. 
The AMORIS cohort had lower mortality 
compared to the population of Stockholm 
County during the period 1985-2012 because 
of a predisposition of gainfully employed 
subjects (Standardized Mortality 
Ratio=0.88).124 By suffering from chronic 
illness, the chance to be employed is lower.146  
The absolute incidence rate of myocardial 
infarction and mortality rate in study II and 
study III would be expected to be lower 
compared to that of the population of the 
greater Stockholm area. However, it is 
unlikely that this would bias the associations 
between fructosamine levels and these 
outcomes. 
Selection of individuals with available 
information could give a selection bias if 
event-related sources such as quality of care 
registers are used. This may lead to a higher 
probability for the cases to be exposed. In 
attempting to avoid potential selection bias, in 
study II and III, we restricted our sensitivity 
analyses to those who had information on 
smoking from research cohorts, the MFR or 
national surveys of living conditions 
exclusively. This restriction limited the 
sample size. 
Confounding 
In randomized clinical trials, risk factors other 
than that under study theoretically should be 
of equal distribution in the randomized 
groups. In contrast, the observational design 
with non-randomized exposure groups 
inevitable suffers from oblique distributions. 
Confounding, is a population phenomenon 
and is present when an extraneous risk factor 
for the disease under study also is associated 
with-, but not affected by-, the exposure of 
interest. Several methods are available for 
controlling confounding.147 By using these 
methods, one attempts to reduce the effect on 
the studied event relation that is associated 
with the potential confounders and eventually 
claim the exposure effect as independent of 
other risk factors. Confounding will 
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frequently remain and result in “residual 
confounding”. The magnitude of residual 
confounding may depend on several factors, 
including misclassification and categorization 
of variables.147 Furthermore, researchers have 
almost never exhaustive access to information 
necessary to claim causality. 
In the present studies, we had information on 
biochemistry markers that potentially could 
present as confounders to any observed 
association between fructosamine and the 
outcomes. By adjusting for a set of relevant 
biochemistry markers, we aimed at reducing 
confounding from those factors. Generally, 
we used the continuous measurement of those 
markers. In all studies, we had access to data 
on occupational activity from national 
censuses and we classified groups of 
socioeconomic status (SES) based on this 
information. For many medical associations, 
SES may be an important confounder.148 
Regarding other major risk factors for 
cardiovascular disease and mortality such as 
smoking and hypertension, we had limited 
information. Yet, in a sensitivity analysis, we 
did not see any major changes in the risk 
estimates when we adjusted for these 
variables (Study II). In a previous study, 
current smoking had no major association 
with hyperfructosemia.106 Hence, per 
definition smoking did not constitute an 
actual confounder on the event relation of 
high fructosamine and cardiovascular disease 
and mortality respectively. On the other hand, 
smoking has been associated with lower 
fructosamine.140 Again, in study III, we had 
limited data on smoking. However, we were 
able to adjust in a subset and smoking 
inferred a change in the risk estimate towards 
the null. 
Information bias 
Misclassification of disease 
In studies II-IV, we obtained all disease 
information and mortality from high quality 
national health and mortality registers. These 
registers, covering census, enable good 
sensitivity and specificity of outcome but a 
certain degree of misclassification will be 
present. Regarding all-cause mortality, there 
is basically no misclassification. Diagnoses of 
MI, obtained from the national inpatient 
register compared to medical records, have 
been validated and considered being of high 
quality.129,149 The specificity for MI is high. It 
is clear that not all MIs are reported as such 
(e.g. silent MIs). Hence, we included in the 
outcome also subjects deceased in CHD 
(Study II). Even so, a reduced sensitivity 
would likely be non-differential as regard to 
fructosamine exposure, and in theory not 
affect the risk ratios.147 Misclassification of 
T2D could be high in sensitivity terms and 
low as regards specificity. Compared to the 
estimated age stratified diabetes prevalence in 
Sweden 2012,150 the corresponding numbers 
as shown in Table 10 for the AMORIS cohort 
were similar. Furthermore, the incidence rates 
in AMORIS corresponds well to those 
estimated nationally (Table 11). Therefore, 
the rates of T2D diagnoses in study IV is 
comparable to current Swedish national 
estimates. This supports the validity of the 
T2D diagnoses used in the present thesis, 
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which were obtained using five data sources 
and primarily the NDR. 
Misclassification of exposure 
If the exposure of interest is misclassified 
independently on disease outcome, the effect 
on the estimated parameter measure (e.g. risk 
ratio, hazard ratio, odds ratio) is generally 
predictable in direction, that is, towards the 
null. In cohort designs, where the exposure is 
collected at start of follow-up this is often the 
case. 
We used high quality measurements of all 
biochemistry markers obtained by the 
CALAB laboratory. Intra-individual and 
inter-individual variations of fructosamine 
was considered as minor misclassified with 
low coefficient of variation (CV%).89 
Similarly, for exposure variables reported in 
study IV, the variation was low for either 
biomarker. Daily variation in fructosamine 
levels could potentially affect the 
measurement of interest and misclassify 
borderline individuals into adjacent exposure 
categories. We assume that this 
misclassification would have occurred 
independently of future disease outcome and 
hence diluted the observed associations 
towards no relation. In study II, we 
categorized fructosamine into multiple 
exposure categories. Primarily, those 
categories were defined in consideration to 
mean levels of HbA1c, where HbA1c started 
to increase at a fructosamine of 2.30 mmol/L 
(prediabetes) and exceeded diabetes cut-off 
(6.5%) at 2.60 mmol/L. The epithets (i.e. 
prediabetes, well-controlled diabetes and 
poorly controlled diabetes) of those 
categories were arbitrarily given because no 
established cut-off values for diabetes are set 
for fructosamine. Still, the relations of the 
defined ranges of fructosamine and MI/CHD 
death and mortality should not be afflicted 
with any major bias. Because the use of 
multiple exposure categories, in theory, the 
predicted direction towards the null 
association could be invalid. However, given 
the observed dose-response relationship of 
fructosamine and outcome the potential bias 
seems to be non-differential (Study II). 
Misclassification of confounders 
In all four studies, we adjusted our estimates 
for potential confounders. Apart from sex and 
age, we primarily adjusted the models for 
other biochemical markers and for these we 
do not believe that there is any major 
misclassification regarding baseline values. 
Furthermore, the use of continuous scale for 
those markers, avoids any potential 
categorization issues.147 In study II, we 
adjusted for smoking and hypertension in 
sensitivity analyses. Information on those 
factors came predominantly from 
questionnaire data and hence a certain degree 
of misclassification most likely exists. Any 
misclassification of potential confounders 
would limit the possibility for valid 
adjustment for the confounding effect of the 
estimated parameter.147 Importantly, we used 
only information collected before the start of 
follow-up and that would reduce any 
differential bias affected by the disease 
outcome.  
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Proportional hazards 
The assumption of proportional hazards (PH 
assumption) across time is integral in Cox PH 
regression. In its essence, it assumes that the 
rate effect of a covariate is constant between 
compared groups at each point in time. Only 
the background rate will vary. We evaluated 
the assumption of proportional hazards by 
inspection of the Schoenfeld residuals138,151 
obtained in the PH modelling, and found their 
correlations with age at the outcome to be 
none or very weak. Conservatively we  
deemed the assumption to hold for the 
covariates included in the fitted models 
(Study II-IV). There were signs of a departure 
from proportionality in the hazard ratio 
comparing men and women thus indicating a 
conjunction between men and women at older 
ages regarding the risk of MI, CHD and T2D. 
We stratified our models by sex rather than 
included it as a covariate. Stratification or 
inclusion of time dependent covariates are 
methods to consider when the PH assumption 
tends to be severely violated. 
Table 10. Prevalence of T2D in 1996, 2004 and 2012 in the AMORIS population. 
  Prevalence (%) of T2D at three calendar years 
  1996 2004 2012 
Age (years) Sex Mean age Prevalence Mean age Prevalence Mean age Prevalence 
35-44 Men 39.6 1.1%  40.0 0.9% 41.3 1.2% 
Women 39.6 0.7% 39.8 0.6% 41.2 1.4% 
45-64 Men 53.6 5.6%  55.2 6.8% 55.3 6.9% 
Women 53.6 2.8% 55.4 3.7% 55.1 4.1% 
≥65 Men 74.3 8.9% 73.4 13.8% 73.5 17.8% 
Women 76.3 6.5% 74.9 9.4% 74.6 11.5% 
ALL Men 51.0 4.5% 57.0 7.5% 63.0 11.7% 
Women 51.9 2.8% 57.7 4.8% 63.6 7.5% 
 
Table 11. Incidence rates of T2D (1996-2012) in the AMORIS population. 
  Incidence rate per 10,000 years in three periods 
Age (years) Sex 1996-2004 2005-2012 1996-2012 
35-44 Men 14.6 (13.5-15.7) 21.5 (19.5-23.5) 16.7 (15.7-17.7) 
Women 9.1 (8.1-10.1) 15.2 (13.5-16.9) 11.2 (10.3-12.1) 
45-64 Men 60.5 (59.0-62.0) 84.5 (82.4-86.6) 70.1 (68.9-71.3) 
Women 33.6 (32.4-34.8) 47.8 (46.2.4-49.6) 39.4 (38.4-40.4) 
≥65 Men 101.5 (98.4-104.6) 134.2 (130.9-137.5) 119.1 (116.8-121.4) 
Women 74.1 (71.6-76.6) 93.1 (90.4-95.8) 84.0 (82.1-85.9) 
ALL (20-) Men 53.1 (52.1-54.1) 90.2 (88.6-91.8) 67.9 (67.0-68.8) 
Women 34.7 (33.9-35.5) 58.6 (57.3-59.9) 44.4 (43.7-45.1) 
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FINDINGS AND IMPLICATIONS 
Study I 
In this population, including individuals in all 
stages of glycemic exposure, we showed how 
three types of glycemic measurements were 
associated at several exposure levels. We 
showed substantial correlation in states of 
hyperglycemia, where the fructosamine vs. 
HbA1c correlation was r=0.75 in both newly 
diagnosed and documented T2D as well as in 
T1D. These high linear correlations 
confirmed previous reports from several 
studies.100-104 In stratified analyses, we 
showed that fructosamine and HbA1c were 
linearly uncorrelated in subjects that were in a 
normoglycemic state, consistent with a 
previous report103 of curvilinear correlation, 
however in a larger population and in another 
setting. As pointed out,106,109 an inverse 
relationship of fructosamine and BMI 
potentially could have biased the correlations 
observed in our study. By adjusting the 
correlations by BMI, we could not show any 
major differences. However, this could 
potentially have implications for the 
interpretation of fructosamine values in 
highly obese diabetes patients but this needs 
to be further studied. 
In addition to linear correlations in a cross-
sectional setting, we showed high correlations 
between fructosamine and HbA1c in 
longitudinally changes. Although this was 
expected, it has not previously been reported.  
With this study, we confirmed previous 
reports 100-105 and added the largest study 
performed to investigate the correlations of  
the glycemic markers under study. It shows 
that fructosamine reflects current glucose and 
HbA1c levels as well as parallel changes over 
time in states of hyperglycemia. In most 
situations, fructosamine levels indicate the 
glycemic exposure similarly as does HbA1c. 
Study II 
The results from this study suggest an 
association of elevated fructosamine with 
incident myocardial infarction as well as with 
all-cause mortality. An increased incidence of 
MI was observed already at fructosamine 
levels indicating prediabetes and the risk of 
an MI was almost three times higher in 
individuals with poorly controlled diabetes 
(as assessed by fructosamine) vs. the 
reference group. The association remained 
after adjustment for socioeconomic status, 
lipids and glucose, which would signify an 
additional influence of fructosamine above 
that of lipids and glucose. We used outcomes 
with comparatively low (MI) or none (all-
cause mortality) misclassification and all 
information on outcomes was obtained from 
the national patient register and national 
mortality register. Loss-to follow-up of 
subjects should not bias the associations. In 
this study, we categorized fructosamine levels 
into clinically relevant sub-groups to simplify 
interpretation of the effects. We also 
modelled the relationship between 
fructosamine and mortality continuously 
rather than in clinically relevant groups and 
found the sharply increased mortality 
associated with elevated fructosamine to 
level-out at around 3.30-3.50 mmol/L. This 
may indicate that extremely high 
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fructosamine values could have another 
underlying mechanism not related to 
hyperglycemia. 
The relation between elevated fructosamine 
and incidence of hard events such as MI and 
death was not extensively investigated until 
2015. Then, we and two other research 
groups independently published results on 
this topic in different populations.105,111,152 All 
these three studies adopted cohort designs and 
estimated hazard ratios for CHD events and 
death at various defined cut-offs for 
fructosamine. In spite of these similarities, 
direct comparisons of the results are difficult 
to accomplish mainly due to different 
population characteristics, choices of 
reference groups and exposure levels. Still, all 
studies showed an increased adjusted hazard 
for a group with higher levels compared to a 
reference group (Figure 12). The model 
adjustments differed between the studies, but 
all used sex, age and lipid related markers. In 
addition, one study showed that subjects with 
well-controlled diabetes had higher hazard of 
CHD disease compared to the non-diabetes 
reference group despite of having lower 
fructosamine.105 Zaccardi et al. refrained from 
concluding an independent effect of 
fructosamine.111 The lack of a significant 
association in this study is most likely due to 
the smaller study size. It is notable that the 
mean fructosamine levels were higher in the 
studies by Selvin et al. and Zaccardi et al. 
compared to the AMORIS study. In contrast 
to our study, which utilized fresh blood for all 
analyses, these other two studies re-analyzed 
long-term frozen samples. In addition, the 
different population characteristics may call 
into questions; what are normal fructosamine 
levels?
 
Figure 12. Comparison of three recent studies on the relationship between fructosamine and CVD events.105,111,152 
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Study III 
We included 215,011 subjects without 
diabetes in this study. All had biochemical 
measurements, including fructosamine, 
performed in a fasting state. It has previously 
been shown how low fasting glucose may be 
associated with an increased mortality.112 Our 
main interest in this study was to characterize 
the mortality across the fructosamine 
continuum in a population without diabetes, 
including very low levels. We showed a 
pattern where all-cause mortality was 
increased in subjects with low and 
intermediate fructosamine levels. Those 
levels concerned up to 80% of the population. 
Importantly, the pattern of fasting glucose 
also showed an increased mortality at low 
levels below 4.4 mmol/L. Several studies 
have previously shown glucose independent 
associations between glycated serum proteins, 
smoking and systemic inflammatory 
markers.140-143 In the ten percent lowest 
fructosamine, we observed a tendency of 
increased chronic inflammation (as indicated 
by increased haptoglobin) and a higher 
proportion of smokers compared to the broad 
reference group. Our observation is in line 
with what has been previously reported140 and 
points towards a role of chronic inflammation 
as a mediating factor between smoking and 
low levels of fructosamine.  
Based on our study results, we could not 
exclude a potential adverse biologic effect of 
low fructosamine in itself but likely, a major 
part of the observed inverse association 
between fructosamine and mortality in this 
population could be explained by smoking 
and a higher amount of systemic 
inflammation. These components may act 
either as confounding or mediation factors. A 
likely similar epiphenomenon was observed 
in the ARIC cohort.105 
Study IV 
With this large prospective study, we found 
expected associations for established risk 
factors of T2D. In addition, we described the 
long-term trajectories of those factors, 
reflecting glycemic and lipid related exposure 
as well as inflammatory processes. The 
trajectories of the population mean values 
were different in T2D cases compared to 
control subjects many years before a 
diagnosis of T2D. This time span of pre-
diagnostic long-term trajectories of risk 
factors have not previously been reported. 
Risk factors, which are associated with 
reduced insulin sensitivity, e.g. BMI, 
triglycerides and uric acid, were higher in 
T2D cases than in control subjects up to 25 
years before the diagnosis. These observed 
elevations, point towards an early presence of 
insulin resistance in subjects who much later 
are diagnosed with T2D. Because of a long-
term presence of insulin resistance, the 
fasting glucose in those subjects starts to 
increase simultaneously. Therefore, a slightly 
increased fasting glucose might serve as an 
indicator of reduced insulin sensitivity and 
may not have autonomous casual properties.  
We estimated absolute risk of T2D after 
stratifying on sex, age, BMI, triglycerides and 
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fasting glucose. Overweight, and in particular 
obesity, strongly increased the risk. This 
suggests that any weight reduction may imply 
protection of developing T2D, which also is 
well documented in primary prevention 
trials.153,154 In addition, weight reduction with 
bariatric surgical procedures, was reported to 
lower the risk of T2D independently of 
baseline BMI.155 The total incidence of T2D 
was higher for men than for women, but at 
corresponding levels of the risk factors, the 
risk was comparable in both genders. Hence, 
a greater propensity to dyslipidemia, 
overweight and obesity was apparent in men. 
This might relate to a tendency for women to 
have better protection, compared to men, in 
developing intraabdominal obesity, also when 
men and women adopt comparable physical 
inactivity and poor dietary habits.156 
The risk prediction model we developed, 
including only a few parameters, which are 
commonly available in clinical practice, 
performed well compared to several other 
risk scores,157 in discriminating cases from 
non-cases. 
We did not include fructosamine in the risk 
prediction model. However, we investigated 
the role of fructosamine in the development 
towards a diagnosis of T2D. We observed a 
crude 16% increased hazard for one standard 
deviation change. When we adjusted for 
triglycerides, only a marginal association 
remained. For cut-offs derived to reflect 
diagnostic levels for prediabetes and diabetes, 
fructosamine was positively associated with 
the incidence of T2D. This may suggest 
fructosamine as a predictor of T2D. 
Fructosamine showed no difference between 
cases and controls during the early years of 
the trajectory, though there was a difference 
at 15 years before a diagnosis. This point in 
time coincides with an average glucose 
indicating prediabetes. In fact, this would be 
in accordance with the results from study I,137 
where we reported no correlation of the 
glycemic markers in states of normal glucose 
tolerance. 
As discussed in the opening background 
chapter of this book, the ARIC study found a 
five-fold increased risk for individuals above 
the 95th percentile of fructosamine, i.e. ≥2.64 
mmol/L.115 In the AMORIS study, we found 
an increased risk for those above the 95th 
percentile of fructosamine (>2.40 mmol/L) 
but the magnitude of this elevated risk was 
smaller. Methodological issues in the 
ascertainment of diagnoses could potentially 
explain parts of the difference. On average, 
the AMORIS cohort reported lower 
fructosamine levels compared to the ARIC 
study, which shows the heterogeneity of 
populations. Further, based on AMORIS 
results, individuals above 2.60 mmol/L are 
already in a hyperglycemic state137 and 
accordingly should be excluded from studies 
of incident diabetes
Håkan Malmström   
58 
 
Future perspectives for fructosamine 
Among alternative tests other than glucose 
itself, HbA1c is the preferred test for the 
diagnosis as well as for long-term control of 
diabetes. Other tests of glycated proteins, 
including fructosamine, are rarely used in 
clinical practice. Growing evidence for the 
usefulness of fructosamine as a 
complementary biomarker for glucose 
metabolism is emerging.105,115,137,152,158 
Despite the demonstrated advantages of the 
HbA1c test,24 there are certain situations 
where HbA1c can fail to reflect glycemic 
exposure accurately,24 e.g. in individuals with 
any disturbance of erythrocyte turnover and 
hemoglobinopathies. In addition, 
unavailability of the test globally, may limit 
its use. In these situations, other 
measurements of long-term glycemic 
exposure merits attention and fructosamine 
might be an alternative after consideration of 
its disadvantages.94,96-99,159 Another possible 
limitation of the HbA1c test is its higher cost 
compared to an ordinary plasma/serum test. 
In large observational cohort studies as well 
as in pharmaceutical RCTs the cost/time 
reduction by exchanging HbA1c with 
fructosamine might be substantial.  
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CONCLUSIONS 
 
Fructosamine is closely associated with HbA1c and glucose respectively and may be a 
useful biomarker of hyperglycemia and glucose control in clinical and epidemiological 
studies. 
The associations were seen particularly in patients with type 1 or type 2 diabetes. Fructosamine and 
HbA1c tend to parallel each other over time in subjects with diabetes indicating similar reflections 
of glucose. The results also suggest that fructosamine discriminates well between subjects with and 
without diabetes. 
High fructosamine levels are associated with an increased risk of acute myocardial 
infarction and death from any cause. 
At high fructosamine levels, these strong associations remained after adjustment for major 
cardiovascular risk factors and glucose levels. Similar associations were obtained by using HbA1c 
as a predictor of risk. Fructosamine can be used either as a single prognostic tool or as a 
complement to HbA1c. 
Low levels of fructosamine in individuals without diabetes were found to be associated 
with increased mortality.  
Smoking and chronic inflammation seem to at least partially explain this association but an 
independent contribution by low fructosamine cannot be excluded.  
Development of T2D is associated with subtle elevations of metabolic risk factors and 
inflammation more than 20 years before diagnosis. 
This suggests that diabetogenic processes tied to chronic insulin resistance operate for decades prior 
to the development of T2D. A simple risk classification can help to early identify individuals at 
increased risk. Fructosamine was increased in cases of T2D compared to controls about 15 years 
before a diagnosis. 
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FUTURE STUDIES 
In this thesis, studies were designed for evaluation of fructosamine in relation to established 
biomarkers of diabetes, to CHD and mortality and in relation to the diagnosis of T2D. Future 
research, based on the AMORIS cohort, intends to investigate the relationship of fructosamine with 
microvascular diseases, prevalent as well as incident, and in particular, diabetic retinopathy. 
Furthermore, better understanding of the relationship between fructosamine and HbA1c in anemic 
conditions, red blood cell disorders and in subgroups of subjects with disorders of the protein 
metabolism, warrants attention.
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SVENSK SAMMANFATTNING 
Diabetes är en sjukdom som definieras av högt 
blodsocker. Sjukdomen är ett stort hälsoproblem 
globalt och ökar dramatiskt risken för hjärt-
kärlsjukdomar och förtida död. För att 
diagnostisera diabetes och även för att kontrollera 
status hos diagnostiserade patienter, används idag 
i stort sett endast två metoder; mätning av 
fasteglukos i blodet och/eller mätning av andelen 
glykerat hemoglobin (HbA1c). Det senare ger en 
uppskattning av hur den genomsnittliga 
glukosnivån har varit de senaste 2-3 månaderna 
medan fasteglukos ger en ögonblicksbild. 
Denna avhandling har som målsättning att 
utvärdera fruktosamin, en annan indikator för 
genomsnittliga blodsockernivåer vilken dock 
avspeglar glukosnivåerna under de senaste 2-3 
veckorna, och på så sätt bidraga med mer kunskap 
om denna markör. Dessutom undersöks 
utvecklingen av flera riskfaktorer, varav 
fruktosamin är en, i ett 25-års perspektiv som 
riskprediktor av typ 2 diabetes. 
I den första studien, jämförde vi de två etablerade 
metoderna för diagnos och kontroll av diabetes 
(fasteglukos och HbA1c) med fruktosamin. Vi såg 
ett starkt linjärt samband mellan alla dessa tre 
markörer vid förhöjda glukosnivåer. Vidare 
förändrades markörerna likartat över tid oavsett 
ökning eller sänkning av nivåerna av de tre olika 
riskmarkörerna. Fruktosamin visade sig också 
förtjänstfullt kunna skilja ut individer med högt 
blodsocker från individer med normala nivåer. 
I den andra studien undersökte vi om det fanns 
samband mellan förhöjda fruktosaminvärden och 
risken för akut hjärtinfarkt och förtida död. I 
modeller där hänsyn togs till kön, ålder, 
socioekonomisk situation och blodfetter, såg vi en 
fördubblad risk för både akut hjärtinfarkt och död 
vilken kunde hänföras till bristande 
glukoskontroll. Även när hänsyn togs till 
glukosnivåer hade fruktosamin en tilläggseffekt 
för bedömning av dessa händelser. Vi 
konstaterade vidare att fruktosamin och HbA1c 
var lika goda prediktorer av framtida hjärt-
kärlsjukdom och död. 
I den tredje studien var fokus på lägre 
fruktosaminnivåer hos individer som inte hade 
diagnostiserad diabetes. Vi såg ett samband 
mellan låga till moderata nivåer och en ökad 
dödlighet. Baserat på känslighetsanalyser tror vi 
att detta samband åtminstone till en del beror på 
skillnader i rökvanor och kronisk inflammation 
men en biologiskt relaterad skadlig effekt av det 
låga fruktosaminet kan inte uteslutas. 
Vi såg i den fjärde studien  att BMI, blodfetter 
och inflammationsmarkörer var genomsnittligt 
högre hos framtida diabetesfall jämfört med 
matchade referensindivider mer än 20 år före 
diagnos. Samtidigt var även fasteglukos högre hos 
fallen om än inte lika uttalat. Vi konstruerade en 
risktabell baserad på kön, ålder, BMI, blodfetter 
och fasteglukos som på ett översiktligt sätt kan 
underlätta vid en bedömning av en individs 
långsiktiga risk att utveckla typ 2 diabetes. 
Sammanfattningsvis visar avhandlingens studier 
på att utvecklingen av typ 2 diabetes börjar tidigt 
och att ett fåtal faktorer på ett enkelt sätt kan 
identifiera individer under hög risk. Vi visade en 
generell användbarhet av fruktosamin som ett 
kliniskt och epidemiologiskt verktyg eftersom det 
avspeglar den underliggande 
blodsockerbelastningen på ett relevant sätt och 
komplementärt till etablerade biomarkörer. 
Sambandet med hjärtinfarkter och förtida död 
visar även på en betydelse av fruktosamin som 
kardiovaskulär riskfaktor. 
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